Chuangyebang was informed that CCOA Therapeutics (hereinafter referred to as “CCOA”) recently announced the successful completion of the Pre-A round of financing. This round of financing was led by Zhejiang Puhua Capital, a well-known domestic investment institution. This is another round of financing of CCOA Group after the completion of the angel round of financing in 2019. The funds raised will be used to accelerate the preclinical development of the company’s world’s first innovative drug for ischemic stroke, CA1001, and the clinical application in China and North America. . Together with the angel round of financing, CCOA has received nearly 100 million yuan in early-stage financing.
CCOA Therapeutics Canada was founded in March 2016 by Professor Ni Heyu, a member of the Canadian Academy of Medical Sciences. It is an innovative drug research and development company focusing on cardiovascular and cerebrovascular diseases, cancer metastasis, rare diseases and bleeding diseases. The company has more than ten product pipelines under research, which are completely independent research and development of innovative products, with competitive differentiation advantages;
It has an internationally leading R&D center in Toronto, including 18 advanced platform technologies and in vivo animal models of more than 20 diseases, which can be widely used in pre-clinical large-scale pharmacology, pharmacokinetics and toxicology evaluation of products under development. Xixiou Ai (Hangzhou) Biopharmaceutical Co., Ltd. was jointly introduced and established in December 2021 by Puhua Capital and Hangzhou Bay Area Data Innovation Technology, which undertakes the functions of the group company’s Asia-Pacific region operating body and China headquarters.
The core team members come from well-known domestic and foreign institutions, multinational companies and drug R&D companies, covering all aspects of drug preclinical development, clinical, corporate management, operations and finance. At the same time, the company also has a number of scientific consultant teams from well-known domestic and foreign research institutions with rich scientific research and clinical experience. The founder and chairman, Dr. Ni Heyu, is an academician of the Canadian Academy of Medical Sciences, a professor at the University of Toronto and a senior scientist at the Canadian National Blood Service. Academician Ni graduated from the Medical Department of Anhui Medical University, and obtained a Ph.D. in Immunology from the University of Manitoba, Canada, and then carried out postdoctoral research in the Department of Pathology at Harvard University.
Academician Ni Heyu said: “We are very honored to be recognized and supported by well-known domestic investment institutions. The aging of my country’s population is accelerating, and there are more than 260 million people over the age of 60. Drug research and development for stroke and cardiovascular and cerebrovascular diseases is to support the “old town Yang Yang”. This round of financing will actively promote the research and development process of the company’s first new drug in the world, especially the completion of the preclinical research and development of our core project CA1001 and the China/Canada clinical double report.
“A large number of previous animal experiments have proved that CA1001 has a fast onset and is highly safe. It has a synergistic effect with tPA and mechanical thrombectomy, which can significantly improve the efficiency of tPA thrombolysis or mechanical thrombectomy, reduce the dosage of tPA, and avoid Intracerebral hemorrhage, expanding the treatment time window, preventing reinfarction, treating reperfusion injury and reducing mortality, etc. Multidimensional effects. In non-human primate experiments, CA1001 demonstrated an excellent therapeutic safety window, with a unique preclinical and clinical advantages, it is expected to fill the international gap in the field of stroke treatment. In addition, CA1001 has great potential in the expansion of indications, including the treatment of coronary heart disease and rare diseases. Disease patients bring good news.”
Mr. Zhou Mi, Managing Partner of PricewaterhouseCoopers, said: “PwC Capital has been committed to bringing the world’s leading medical technology and top scientists into China. Academician Ni Heyu is a widely respected expert in the field of international thrombosis and hemostasis. The universities have achieved fruitful scientific research achievements, and we believe that CCOA will make use of its comprehensive advantages at home and abroad to contribute to the progress of breakthrough new drugs for cardiovascular and cerebrovascular diseases.”
attached
For more project information, please go to ” Analysis of Rui Beast “.
media coverage
Yiou Venture Capital Investment Circle
Related events
- “West West Europe Ai” announced the completion of Pre-A round of financing, led by Zhejiang Puhua Capital2022-08-04
- Doyle Bio received tens of millions of yuan in Series A financing to promote the research and development of multi-domain biological drugs2019-02-13
- ” Xianweida Bio” received nearly 200 million yuan in Series A financing2019-02-13
- Lansheng Biopharmaceutical completed tens of millions of A round of financing2019-01-28
- Udao Bio completed the Pre-A round of financing invested by Fosun Pharma2019-01-14
This article is reprinted from: https://readhub.cn/topic/8iaR9SzOtRc
This site is for inclusion only, and the copyright belongs to the original author.